Burden of high fracture probability worldwide: secular increases 2010–2040

Osteoporosis International

Volumn 26, Issue 9, 2015, Pages 2243-2248

  Oden A ^b   McCloskey, E V ^b   Kanis, J A ^b   Harvey, N C ^a   Johansson, H ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Burden of disease; Epidemiology; Fracture probability; FRAX; Intervention threshold; Osteoporosis

Indexed keywords

ADULT; AFRICA; AGE; AGED; ARTICLE; ASIA; CENTRAL AMERICA; EPIDEMIC; EUROPE; FEMALE; FRAGILITY FRACTURE; HIGH RISK POPULATION; HUMAN; MALE; MIDDLE AGED; NORTH AMERICA; PACIFIC ISLANDS; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; SOUTH AMERICA; VERY ELDERLY; AGE DISTRIBUTION; COST OF ILLNESS; HEALTH; OSTEOPOROTIC FRACTURES; PROCEDURES; SEX RATIO; STATISTICS AND NUMERICAL DATA; TRENDS;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COST OF ILLNESS; FEMALE; GLOBAL HEALTH; HUMANS; MALE; MIDDLE AGED; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT; SEX DISTRIBUTION;

EID: 84938989419     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3154-6     Document Type: Article

References (42)

1. Vos T, Flaxman AD, Naghavi M et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study. 2010. Lancet 380(9859):2163–2196
2. Murray CJ, Vos T, Lozano R et al (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2197–2223
3. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H et al (2012) A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2224–2260
4. Cooper C, Campion G, Melton LJ III (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285–289
5. Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407–413
6. Johnell O, Kanis JA (2004) An estimate of the world-wide prevalence, disability and mortality associated with hip fracture. Osteoporos Int 15:897–902
7. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733
8. Odén A, McCloskey EV, Johansson H, Kanis JA (2013) Assessing the impact of osteoporosis on the burden of hip fractures. Calcif Tissue Int 92:42–49
9. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046
10. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141
11. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42:467–475
12. Johansson H, Kanis JA, Oden A, Compston J, McCloskey E (2012) A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporos Int 23:907–915
13. Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP/EWP/552/95Rev.2. London, CHMP. Nov 2006
14. Kanis JA, Hans D, Cooper C, and the Task Force of the FRAX Initiative et al (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:395–411
15. Kanis JA, Borgström F, Compston J, Dreinhöfer K, Nolte E, Jonsson L, Lems WF, McCloskey EV, Rizzoli R, Stenmark J (2013) SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos 8:144. doi:10.1007/s11657-013-0144-1
16. Kanis JA, Johansson H, Oden A, Cooper C, McCloskey EV, and the Epidemiology and Quality of Life Working Group of IOF (2013) Worldwide uptake of FRAX. Arch Osteoporos 8:166. doi:10.1007/s11657-013-0166-8
17. Compston J, Cooper A, Cooper C, on behalf of the National Osteoporosis Guideline Group (NOGG) et al (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105–108
18. Lekawasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, for the Joint IOF-ECTS GIO Guidelines Working Group et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257–2276
19. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y, on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57
20. Briot K, Cortet B, Thomas T et al (2012) 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Bone Joint Spine 79:304–313
21. Grigorie D, Sucaliuc A, Johansson H, Kanis JA, McCloskey E (2013) The application of FRAX® to determine intervention thresholds for osteoporosis in Romania. Arch Osteoporos 8:164
22. Johansson H, Kanis JA, McCloskey EV, Odén A, Devogelaer J-P, Kaufman J-M, Neuprez A, Hiliigsmann M, Bruyere O, Reginster JY (2010) A FRAX® model for the assessment of fracture probability in Belgium. Osteoporos Int 22:453–461
23. Kanis JA (2013) Commentary on guidelines on postmenopausal osteoporosis—Indian Menopause Society. J Midlife Health 4:129–131
24. Lekamwasam S (2013) Sri Lankan FRAX model and country specific intervention thresholds. Arch Osteoporos 8(1-2):148. doi:10.1007/s11657-013-0148-x
25. Lippuner K, Johansson H, Kanis JA, Rizzoli R (2010) FRAX® assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21:381–390
26. McGowan B, Kanis JA, Johansson H, Silke C, Whelan B (2013) Development and use of FRAX in the management of osteoporosis in Ireland. Arch Osteoporos 8(1-2):146. doi:10.1007/s11657-013-0146-z
27. Russian Association on Osteoporosis (2013) http://www.osteoporoz.ru/content/view/891/113/
28. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. doi:10.1007/s11657-013-0136-1
29. Strom O, Borgström F, Kanis JA, Compston JE, Cooper C, McCloskey E et al (2011) Osteoporosis: burden, health care provision and opportunities in the EU. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6:59–155. doi:10.1007/s11657-011-0060-1
30. Lippuner K, Johansson H, Borgström F, Kanis JA, Rizzoli R (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. Osteoporos Int 23:2579–2589
31. Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6(29):1–255
32. Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl D, Cyrus Cooper C, on behalf of the IOF Working Group on Epidemiology and Quality of Life (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23:2239–2256
33. United Nations (2010) World Population prospects, the 2010 revision. Department of Economic and Social Affairs, UN (http://esa.un.org/unpd/wpp/unpp/panel_indicators.htm) Accessed Feb 2014
34. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427
35. Johansson H, Kanis JA, Oden A, Compston J, McCloskey E (2012) A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporos Int 23:907–915
36. Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767
37. Felsenberg D, Silman AJ, Lunt M et al (2002) Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study Epos. J Bone Min Res 17:716–724
38. Johnell O, Gullberg B, Kanis JA (1977) The hospital burden of vertebral fracture in Europe: a study of national register sources. Osteoporos Int 7:138–144
39. Johnell O, Kanis JA (2005) Epidemiology of osteoporotic fractures. Osteoporos Int 16(suppl 2):S3–S7
40. Siggeirsdottir K, Aspelund T, Johansson H, Gudmundsson EF, Mogensen B, Jonsson BY et al (2014) The incidence of a first major osteoporotic fracture in Iceland and implications for FRAX. Osteoporos Int 25:2445–2451
41. Lam A, Leslie WD, Lix LM, Yogendran M, Morin SN, Majumdar SR (2014) Major osteoporotic to hip fracture ratios in Canadian men and women with Swedish comparisons: a population-based analysis. J Bone Miner Res 29:1067–1073
42. Kanis JA, Johansson H, Odén A, McCloskey EV (2012) The distribution of FRAX® based probabilities in women from Japan. J Bone Miner Metab 30:700–705